The antioxidant response as a drug target in diabetic neuropathy.
While increasing antioxidant potential is an attractive treatment strategy for diabetic neuropathy, many years of trials using high-dose oral antioxidants have not produced therapeutic results. An increasing understanding of the innate antioxidant response and the pharmacological agents that can regulate this mechanism may open new avenue for drug development. This review describes the current state of antioxidant trials and the potential for targeting the antioxidant response. In combination with antihyperglycemic agents, agents that regulate the antioxidant response may afford superior protection against cellular oxidative injury in diabetes.
Vincent
Andrea M
AM
Department of Neurology, University of Michigan, Ann Arbor, MI 48109, USA. andreav@umich.edu
Edwards
James L
JL
Sadidi
Mahdieh
M
Feldman
Eva L
EL
D000818:Animals; D000975:Antioxidants / Q000378:metabolism / Q000494:pharmacology*; D002986:Clinical Trials as Topic; D003920:Diabetes Mellitus / Q000503:physiopathology; D003929:Diabetic Neuropathies / Q000188:drug therapy* / Q000503:physiopathology; D016503:Drug Delivery Systems; D004359:Drug Therapy, Combination; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use; D018384:Oxidative Stress / Q000187:drug effects*
D000975:Antioxidants; D007004:Hypoglycemic Agents